TU Dresden


Selective Neuronal Vulnerability in Neurodegenerative Diseases - Dr. Natalia Rodriguez Muela


In most neurodegenerative diseases certain neuronal subgroups degenerate fast while others, carrying the same mutations -if any-, subjected to theoretically analogous stress and displaying comparable functional properties remain unaffected, even at the latest stages of the disease. Motor neuron diseases are a group of disorders in which motor neurons (MNs) of the spinal cord and/or the motor cortex are the primary cell type affected where this perplexing feature can also be observed. Using a variety of approaches ranging from cellular biology techniques and live imaging to genome editing and single cell genomics, and utilizing hiPSC together with transgenic animal models, we investigate the molecular mechanisms underlying such selective MN death. We devote a special focus at exploring the molecular basis of proteostasis failure -major causative event in neurodegeneration-, and at examining the contribution of cell autonomous and non-cell autonomous factors to the selective MN loss. Our ultimate goal is to understand the molecular origin of this distinctive neuronal vulnerability to design effective therapeutics targeting specific neuronal subtypes or phases of the disease.

Previous and current research

The key aspect of selective motor neuron death in motor neuron diseases had been difficult to address using available mouse models. We use as main model system a human induced pluripotent stem cell (iPSC)-based approach and discovered that even within a single genetic background, MNs display a wide diversity of SMN levels – protein essential for MN survival –, and that those cells with low SMN are more susceptible to die. This correlation holds true in MNs expressing mutations causing the most common motor neuron diseases (amyotrophic lateral sclerosis or ALS and spinal muscular atrophy or SMA) and even in MNs obtained from unaffected patients.

This discovery led to a new understanding of the importance of cell diversity in the progression of these diseases and helped to explain why there is a “survivor” population of MNs. However, there is so much that we still ignore. Some of the question that we want to answer are: what are the main similarities and differences between the surviving ALS and SMA MNs are there factors/pathways shared between neuronal types unaffected in MNDs that explain their protection?, what is the molecular basis of SMN heterogeneity across MN populations? Ultimately, why do many neurons degenerate while some remain fully resistant?

Future projects and goals

  • Investigate the origin of the heterogeneity in the levels of proteins essential for MN survival.
  • Explore cell-autonomous similarities and differences between surviving and affected SMA and fALS MNs.
  • Explore the contribution of a dysregulation of the autophagy-lysosome axis to the selective MN loss.
  • Unravel the molecular mechanisms that explain the protection of other neuronal types unaffected in motor neuron diseases.

Selected publications

Rodriguez-Muela N*, Parkhitko A, Grass T, Gibbs R, Norabuena E, Perrimon N, Singh R, Rubin LL*. Blocking p62/SQSTM1- dependent SMN degradation ameliorates the Spinal Muscular Atrophy disease phenotype. J Clin Invest. 2018 Jul 2;128(7):3008-3023. doi: 10.1172/JCI95231. (*Corresponding authors).

Patricia Boya*, Patrice Codogno and Natalia Rodriguez-Muela*. Autophagy in stem cells: repair, remodeling, and metabolic reprogramming. Development. 2018 Feb 26;145(4). doi: 10.1242/dev.146506. (*Corresponding authors).

Tripathi P, Rodriguez-Muela N, Klim JR, de Boer AS, Agrawal S, Sandoe J, Lopes CS, Ogliari KS, Williams LA, Shear M, Rubin LL, Eggan K, Zhou Q. Reactive Astrocytes Promote ALS-like Degeneration and Intracellular Protein Aggregation in Human Motor Neurons by Disrupting Autophagy through TGF-β1. Stem Cell Reports. 2017 Aug 8;9(2):667-680. doi: 10.1016/j.stemcr.2017.06.008.

Palomo V, Perez DI, Roca C, Anderson C, Rodríguez-Muela N, Perez C, Morales-Garcia JA, Reyes JA, Campillo NE, Perez-Castillo AM, Rubin LL, Timchenko L, Gil C, Martinez A. Subtly Modulating Glycogen Synthase Kinase 3 β: Allosteric Inhibitor Development and Their Potential for the Treatment of Chronic Diseases. J Med Chem. 2017 Jun 22;60(12):4983-5001. doi: 10.1021/acs.jmedchem.7b00395.

Rodriguez-Muela N1*, Litterman NK1, Norabuena EM, Mull JL, Galazo MJ, Sun C, Ng SY, Makhortova NR, White A, Lynes MM, Chung WK, Davidow LS, Macklis JD, Rubin LL*. Single-Cell Analysis of SMN Reveals Its Broader Role in Neuromuscular Disease. Cell Reports. 2017 Feb 7;18(6):1484-1498. doi: 10.1016/j.celrep.2017.01.035. (1Equal contribution).

Group members


Group Leader

Dr. Natalia Rodriguez-Muela

+49 (0)351 210463701